Royalty Pharma plc (RPRX)

Royalty Pharma Stock Forecast

Stock Price Forecast

The 5 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 41.6, with a low estimate of 28 and a high estimate of 51. The average target predicts an increase of 28.16% from the current stock price of 32.46.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$28	$41.6	$40	$51
Change	-13.74%	+28.16%	+23.23%	+57.12%

* Price targets were last updated on Oct 25, 2024.

Analyst Ratings

The average analyst rating for Royalty Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	3	3	3	3	3	3
Buy	2	2	2	2	2	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Baum Citigroup	Citigroup	Strong Buy Maintains $60 → $40	Strong Buy	Maintains	$60 → $40	+23.23%	Oct 25, 2024
Chris Shibutani Goldman Sachs	Goldman Sachs	Strong Buy Maintains $50 → $51	Strong Buy	Maintains	$50 → $51	+57.12%	Aug 14, 2024
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Maintains $48 → $51	Buy	Maintains	$48 → $51	+57.12%	Jul 11, 2024
Ashwani Verma UBS	UBS	Strong Buy → Hold Downgrades $28	Strong Buy → Hold	Downgrades	$28	-13.74%	Jun 3, 2024
Geoff Meacham B of A Securities	B of A Securities	Strong Buy Maintains $40 → $38	Strong Buy	Maintains	$40 → $38	+17.07%	Apr 12, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

3.02B

Increased by 33.46%

from 2.26B

Revenue Next Year

3.16B

Increased by 4.44%

from 3.02B

EPS This Year

4.79

Increased by 150.56%

from 1.91

EPS Next Year

5.34

Increased by 11.54%

from 4.79

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.12B	2.29B	2.24B	2.35B	2.26B	3.02B	3.16B	3.49B
Revenue Growth	16.98%	7.87%	-2.28%	5.24%	-3.86%	33.46%	4.44%	10.49%
EPS	1.32	1.49	0.10	2.53	1.91	4.79	5.34	6.05
EPS Growth	-	12.97%	-93.44%	2,490.73%	-24.54%	150.56%	11.54%	13.16%
Forward PE	-	-	-	-	-	6.78	6.07	5.37
No. Analysts	-	-	-	-	-	11	11	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	3.7B	3.8B	4.1B
Avg	3.0B	3.2B	3.5B
Low	2.4B	2.6B	2.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	63.1%	25.0%	31.3%
Avg	33.5%	4.4%	10.5%
Low	5.8%	-13.0%	-17.4%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	6.34	7.18	8.06
Avg	4.79	5.34	6.05
Low	3.94	4.15	4.61

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	231.7%	49.9%	50.9%
Avg	150.6%	11.5%	13.2%
Low	106.1%	-13.5%	-13.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.